Buy Like Buffett
Watchlist

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

TEVA · Healthcare · $35.4B mkt cap · FY2025 filings · · not refreshed in 35 days · Shallow moat ·

Doesn't clear the bar

Shallow moat
Share / Embed this score
Embed this score

The five investor questions

69

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $15.9B to $17.3B, increasing; diluted EPS 0.38 to 1.21, increasing.

79

Median gross margin 48.0% over 10y, very stable.

7

Median ROIC -4.3%, above the 12% hurdle in 20% of years.

56

Net cash position — no leverage risk.

55

Owner earnings changed +8.1%/yr over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
4589% above value if growth stopped today
$68M
$0.66
$0.66
$30.81
4589% above value if growth stopped today

What today’s price assumes: owner earnings growing ~116%/yr over 5 years. The zero-growth estimate assumes owner earnings stay flat (0% growth).

How to read this

We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.

Score records captured Jul 26, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY

Missing a usable price or zero-growth estimate: ANF, BKNG.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

12 years of fundamentals

The business, in plain English

TEVA PHARMACEUTICAL INDUSTRIES LIMITED booked $17.3B of revenue in FY2025 in the Healthcare sector and kept 51.8% of it as gross profit — a solid-margin business by that measure. After every other cost, 8.2% of each revenue dollar reached the bottom line.

Across the filed record, revenue shrank from $19.7B (FY2015) to $17.3B (FY2025) — about −1.3% a year compounded over 10 years.

It earned 34.9% on invested capital in the latest filed year, FY2025. Across the full 11-year measurable filed record, median ROIC was −2.4%. Over the v3 recent window (10 measurable filed years), median ROIC was −4.3%. The Returns on Capital filter above scores it 7/100.

The balance sheet carried $1.8B of total debt in FY2025 against $1.9B of owner earnings — roughly 1.0 years of owner earnings to retire it all. Balance-Sheet Safety scores it 56/100.

Put together: Pricing Power is the strongest of the five filters (79/100) and Returns on Capital the weakest (7/100), which is how TEVA lands at 53/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2014–FY2025 · 12 fiscal years, normalized from TEVA’s SEC filings

Sales, as filed$17.3B FY2025
$0$10B$20B2014201820222025
Revenue kept after cost of goods51.8% FY2025
0%25%50%2014201820222025
Standard ROIC or separately labeled Operating ROICROIC 34.9% FY2025
0%2014201820222025
Cash an owner could take out$1.9B FY2025
−$10B$02014201820222025

Gaps in a line mean that item isn’t in TEVA’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How TEVA PHARMACEUTICAL INDUSTRIES LIMITED makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$17.3B · 100%Cost of revenue$8.3B · 48%Gross profit$8.9B · 52%Operating income$2.2B · 12%Income before tax$1.2B · 7%Income tax−$180M · −1%Net income$1.4B · 8%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$17.3B100%
Cost of revenue$8.3B48%
$8.9B52%
$2.2B12%
Income before tax$1.2B7%
Income tax−$180M−1%
$1.4B8%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

What TEVA PHARMACEUTICAL INDUSTRIES LIMITED owns — and owes

TEVA PHARMACEUTICAL INDUSTRIES LIMITED's filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$40.7B100%
Cash and equivalents$3.6B9%
$1.8B4%
Stockholders’ equity$7.9B19%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What drives TEVA PHARMACEUTICAL INDUSTRIES LIMITED’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity21%Tax burden115%net income ÷ pretax incomeInterest burden57%pretax ÷ operating incomeOperating margin12%operating income ÷ revenueAsset turnover0.43×revenue ÷ average assetsEquity multiplier6.03×average assets ÷ average equityAs of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
$1.4BFY2025
Income before tax$1.2BFY2025
Operating income$2.2BFY2025
$17.3BFY2025
Ending assets$40.7BFY2025
Beginning assets$39.3BFY2024
$7.9BFY2025
$5.4BFY2024
Source:
  • SEC filingFiling detailsAccession 0001193125-25-020826
  • SEC filingFiling detailsAccession 0001193125-26-034532
· event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where TEVA PHARMACEUTICAL INDUSTRIES LIMITED's cash went

TEVA PHARMACEUTICAL INDUSTRIES LIMITED’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations$1.6B100%
Depreciation and amortization$1.0B61%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited1 not holding1/19 resolved18 not retrieved

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Markel / Markel-GaynerNo position reportedNo position reported
Abrams CapitalNot retrievedComparison not retrievedFiling not retrieved
Akre CapitalNot retrievedComparison not retrievedFiling not retrieved
Baupost GroupNot retrievedComparison not retrievedFiling not retrieved
Berkshire HathawayNot retrievedComparison not retrievedFiling not retrieved
Brave Warrior AdvisorsNot retrievedComparison not retrievedFiling not retrieved
Dodge & CoxNot retrievedComparison not retrievedFiling not retrieved
First EagleNot retrievedComparison not retrievedFiling not retrieved
FundsmithNot retrievedComparison not retrievedFiling not retrieved
Gardner Russo & QuinnNot retrievedComparison not retrievedFiling not retrieved
Gates Foundation TrustNot retrievedComparison not retrievedFiling not retrieved
Mairs & PowerNot retrievedComparison not retrievedFiling not retrieved
Oakmark / Harris AssociatesNot retrievedComparison not retrievedFiling not retrieved
Pershing SquareNot retrievedComparison not retrievedFiling not retrieved
Polen CapitalNot retrievedComparison not retrievedFiling not retrieved
Sequoia / Ruane CunniffNot retrievedComparison not retrievedFiling not retrieved
Southeastern Asset ManagementNot retrievedComparison not retrievedFiling not retrieved
Tweedy, BrowneNot retrievedComparison not retrievedFiling not retrieved
Yacktman Asset ManagementNot retrievedComparison not retrievedFiling not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: · event Jun 30, 2026 · retrieved Jul 26, 2026

Flagship explainer

What TEVA PHARMACEUTICAL INDUSTRIES LIMITED insiders reported

We could not retrieve insider activity for this rendering; no zero-activity claim is shown.

Unavailable: Form 4 activity could not be retrieved for this rendering.

Moat Score history

16 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale53.1 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for TEVA.

Healthcare context

#153 of 710 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #151OWLT OWLET, INC.53.4Shallow moat
  2. #152LFST LifeStance Health Group, Inc.53.4Shallow moat
  3. #154ZIVO ZIVO BIOSCIENCE, INC.53.1Shallow moat
  4. #155BCRX BIOCRYST PHARMACEUTICALS, INC.52.9Shallow moat

Compare TEVA with its nearest peers →All Healthcare companies on the Index →

Common questions about TEVA

Does TEVA PHARMACEUTICAL INDUSTRIES LIMITED have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) 53.1 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 69, pricing power 79, returns on capital 7, balance-sheet safety 56, capital allocation 55.
Is TEVA trading below the conservative owner-earnings estimate?
The value if growth stopped today — a zero-growth baseline — is $0.66 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $30.81, that is 4589% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has TEVA's Moat Score changed over time?
The record logs 16 readings since Jul 17, 2026; the latest reads 53.1 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell TEVA. See the disclaimer.